Brismar B, Malmborg A S, Tunevall G, Wretlind B, Bergman L, Mentzing L O, Nyström P O, Kihlström E, Bäckstrand B, Skau T
Huddinge Hospital, Sweden.
Antimicrob Agents Chemother. 1992 Dec;36(12):2766-73. doi: 10.1128/AAC.36.12.2766.
In order to compare the clinical and microbiological efficacies and safety of piperacillin plus tazobactam with those of imipenem plus cilastatin, 134 patients with intra-abdominal infections (73 patients with appendicitis) participated in an open randomized comparative multicenter trial. A total of 40 men and 29 women (mean age, 53 years; age range, 18 to 92 years) were enrolled in the piperacillin-tazobactam group and 40 men and 25 women (mean age, 54 years; age range, 16 to 91 years) were enrolled in the imipenem-cilastatin group. The patients received either piperacillin (4 g) and tazobactam (500 mg) every 8 h or imipenem and cilastatin (500 mg each) every 8 h. Both regimens were given by intravenous infusion. A total of 113 patients were clinically evaluable. Of 55 patients who received piperacillin-tazobactam, 50 were clinically cured, while 40 of 58 patients in the imipenem-cilastatin group were clinically cured. The differences were significant (Wilcoxon test; P = 0.005). There were 4 failures or relapses in the piperacillin-tazobactam group and 18 failures or relapses in the imipenem-cilastatin group. The microorganisms isolated were eradicated in similar proportions in the two patient groups. Adverse reactions, mainly gastrointestinal disturbances and nausea, were noted in 13 patients who received piperacillin-tazobactam and in 14 patients who received imipenem-cilastatin. Results of the present study show that piperacillin-tazobactam is effective and safe for the treatment of intra-abdominal infections.
为比较哌拉西林加他唑巴坦与亚胺培南加西司他丁的临床、微生物学疗效及安全性，134例腹腔内感染患者（73例阑尾炎患者）参与了一项开放性随机对照多中心试验。哌拉西林 - 他唑巴坦组共纳入40例男性和29例女性（平均年龄53岁；年龄范围18至92岁），亚胺培南 - 西司他丁组共纳入40例男性和25例女性（平均年龄54岁；年龄范围16至91岁）。患者每8小时接受一次哌拉西林（4g）和他唑巴坦（500mg）或亚胺培南和西司他丁（各500mg）静脉输注。共有113例患者可进行临床评估。接受哌拉西林 - 他唑巴坦治疗的55例患者中，50例临床治愈，而亚胺培南 - 西司他丁组58例患者中有40例临床治愈。差异具有统计学意义（Wilcoxon检验；P = 0.005）。哌拉西林 - 他唑巴坦组有4例治疗失败或复发，亚胺培南 - 西司他丁组有18例治疗失败或复发。两组患者分离出的微生物被根除的比例相似。接受哌拉西林 - 他唑巴坦治疗的13例患者和接受亚胺培南 - 西司他丁治疗的14例患者出现了不良反应，主要为胃肠道不适和恶心。本研究结果表明，哌拉西林 - 他唑巴坦治疗腹腔内感染有效且安全。
